Against adenoma and parkinsonism
A large observational study conducted by a group from the University of Iowa has provided convincing evidence that some alpha-1 blockers are potentially able to prevent or slow the development of Parkinson's disease.
The researchers analyzed data from nearly 300,000 older men from two large independent databases: Truven Health Analytics MarketScan in the United States and national health registries in Denmark.
Previous preclinical studies on animal models have shown that the alpha-1-adrenoblocker terazosin, prescribed for benign prostatic hyperplasia, increases the supply of cellular energy and can prevent or slow the progression of Parkinson's disease.
To find out whether terazosin or related drugs, which also increase cellular energy production, can reduce the risk of developing Parkinson's disease, the researchers identified 150,000 men who recently started taking terazosin or similar drugs, and compared their data, based on age and medical history, with 150,000 men who first started taking tamsulosin.
Tamsulosin is another selective alpha–1-adrenoblocker prescribed for the treatment of benign prostatic hyperplasia, but, unlike terazosin, it does not affect the production of cellular energy and therefore, according to the authors, does not have a neuroprotective effect.
The researchers analyzed data on the health status of these men and determined how many in each group developed Parkinson's disease. It turned out that men who took terazosin were 12-37% less likely to develop Parkinson's disease during follow-up than men who took tamsulosin. In addition, the study showed that a longer intake of terazosin was associated with an increase in its protective effect on the nervous system.
Despite the relative differences in the structure of the population and the health care system, the protective effect in both countries was comparable, and the reproduction of the results in the international cohort is convincing evidence of a causal relationship. If these results are confirmed in randomized clinical trials, terazosin can be used for neuroprotection to prevent, not just treat, Parkinson's disease.
Article by J.E.Simmering et al. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson's Disease is published in the journal JAMA Neurology.
Aminat Adzhieva, portal "Eternal Youth" http://vechnayamolodost.ru based on the materials of the University of Iowa: Prostate drug associated with lower risk of Parkinson's disease.